Abstract #1161911: Acute Renal Failure: A Rare and Uncommon Side Effect of Semaglutide

Glucagon-like peptide-1(GLP-1) receptor agonists play a significant role in treating type 2 diabetes and obesity. Their extended half-life allows for once-weekly injections1. Semaglutide has cardioprotective and renoprotective effects2 with decreased cardiovascular death rates, nonfatal myocardial infarction, or nonfatal stroke3. SUSTAIN 6 trial, a post hoc analysis that assessed its effects on mean estimated glomerular filtration rate (eGFR), did not show adverse renal outcomes regardless of baseline renal function4.